PSA Testing Guidelines
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses PSA testing guidelines.
Clinical Pearls
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses PSA testing guidelines.
- Rather than focus on one guideline or another, physicians should focus on a model of informed decision making
- A dichotomy exists between those that treat prostate cancer and those that do not
- PSA testing adds value but also brings a potential for harm
- Following PSA testing, a physician should be open to the concept of surveillance before making a decision
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
